Pacific Biosciences of California, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US69404D1081
USD
2.52
0.2 (8.62%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Pacific Biosciences of California, Inc. stock-summary
stock-summary
Pacific Biosciences of California, Inc.
Pharmaceuticals & Biotechnology
Pacific Biosciences of California, Inc. designs, develops and manufactures sequencing systems to help scientists resolve genetically complex problems. The Company is engaged in the development, manufacturing and marketing of an integrated platform for genetic analysis. Its Single Molecule, Real-Time (SMRT) technology enables single molecule, real-time detection of biological processes. It offers The SMRT Cell, Phospholinked nucleotides and The PacBio RS II and Sequel instruments. Its SMRT technology enables the observation of deoxyribonucleic acid (DNA) synthesis as it occurs in real-time by harnessing the natural process of DNA replication, which is actuated by the DNA polymerase. Its phospholinked nucleotides have a fluorescent dye attached to the phosphate chain of the nucleotide rather than to the base. The PacBio RS II and Sequel instruments include optics, automated liquid handling, a touchscreen control interface and computational hardware and software.
Company Coordinates stock-summary
Company Details
1305 O'brien Drive , MENLO PARK CA : 94025
stock-summary
Tel: 1 650 5218000
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 67 Schemes (44.74%)

Foreign Institutions

Held by 133 Foreign Institutions (31.18%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Dr. John Milligan
Independent Chairman of the Board
Mr. Christian Henry
President, Chief Executive Officer, Director
Dr. Michael Hunkapiller
Director
Ms. Kathy Ordonez
Director
Dr. David Botstein
Independent Director
Mr. William Ericson
Independent Director
Mr. Randall Livingston
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
40 Million
(Quarterly Results - Jun 2025)
Net Profit:
-42 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 375 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

5.40

stock-summary
Return on Equity

-900.80%

stock-summary
Price to Book

6.11